A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

Phase 3

Active, not recruiting

• Conditions: IgG4 Related Disease
• Interventions: Drug: Inebilizumab; Other: Placebo

• Registration Number: NCT04540497
• Lead Sponsor: Amgen

Brief Summary

This study aims to evaluate the efficacy and safety of inebilizumab for the prevention of flare of Immunoglobulin G4-related disease (IgG4-RD).

Detailed Description

After a screening period of up to 28 days, subjects with IgG4-RD at high risk of flare due to multi-organ disease and recent active disease will be randomized in a 1:1 ratio to receive intravenous (IV) inebilizumab or placebo after premedication during the 52-week randomized control period (RCP). All subjects will receive an initial tapering dose of glucocorticoids (GCs) to complete treatment of their active disease. Flares occurring during study will be treated. The primary endpoint is time to a first adjudication committee-determined, investigator-treated disease flare during the RCP. The primary analysis will be conducted when the last subject completes the RCP visit or discontinues the RCP. This study includes an optional 3-year open-label treatment period. The study also includes a Safety Follow-up Period (SFUP) after IP discontinuation of up to 730 days. The expected duration of each subject's participation in this study is up to 400 days (screening and RCP), plus up to 1095 days for eligible subjects who enroll in the optional open label period (OLP), and up to 730 days for the SFUP after IP discontinuation, for a total maximum duration of up to 2273 days (screening, RCP, interval between RCP and OLP, OLP, and FSUP).

Study acquired from Horizon in 2024.

Study Timeline

• Study First Submitted: 2020-09-01
• Study First Submitted QC: 2020-09-01
• Study First Posted: 2020-09-07
• Study Start: 2020-10-26
• Primary Completion: 2024-04-09
• Status Verified: 2024-11
• Disposition First Posted: 2024-11-05
• Disposition First Submitted: 2025-03-31
• Last Update Submitted: 2025-03-31
• Last Update Posted: 2025-04-02
• Study Completion: 2028-10-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 135

Inclusion Criteria

1. Male or female adults, ≥ 18 years of age at time of informed consent.
2. Clinical diagnosis of IgG4-RD.
3. Fulfillment of the 2019 ACR/EULAR classification criteria.
4. Experiencing (or recently experienced) an IgG4-RD flare that requires initiation or continuation of glucocorticoid (GC) treatment at the time of informed consent.
5. IgG4-RD affecting at least 2 organs/sites at any time in the course of IgG4-RD
6. Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use a condom with spermicide from Day 1 through to the end of the study and must agree to continue using such precautions for at least 6 months after the final dose of IP. Females of childbearing potential who are sexually active with a non-sterilized male partner must use a highly effective method of contraception

Key

Exclusion Criteria

1. History of solid organ or cell-based transplantation or known immunodeficiency disorder.
2. Active malignancy or history of malignancy that was active within the last 10 years (some specific situations for cervical, skin or prostate cancer are acceptable).
3. Receipt of any biologic B cell-depleting therapy or non-depleting B-cell-directed therapy in the 6 months prior to screening.
4. Receipt of non-biologic DMARD or immunosuppressive agent other than GCs within 4 weeks prior to screening.
5. Active tuberculosis or high risk for tuberculosis; hepatitis C infection in absence of curative treatment; evidence of hepatitis B infection.
6. Receipt of live vaccine or live therapeutic infectious agent within 2 weeks prior to screening.
7. Estimated glomerular filtration rate < 30 mL/min/1.73 m^2.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
VIB0551	Inebilizumab	Inebilizumab administered as an IV infusion.
Placebo	Placebo	Placebo administered as an IV infusion.

Primary Outcome Measures

Name	Time	Method
Time to disease flare, defined as the time in days from Day 1 (dosing) to the date of the first treated and Adjudication Committee-determined IgG4 RD flare within the 52-week RCP.	Day 1 to Day 365

Secondary Outcome Measures

Name	Time	Method
Number of participants with Treatment Emergent Adverse Events of Special Interest (TE AESIs)	Day 1 to Day 2273
Number of Participants with positive Anti Drug Antibodies (ADAs) directed against inebilizumab	Day 1 to Day 365
Annualized flare rate for Adjudication Committee (AC) determined flares	Day 1 to Day 365
Proportion of participants achieving flare-free complete remission	Day 1 to Day 365
Annualized flare rate for AC-determined treated flares	Day 1 to Day 365
Annualized flare rate for AC-determined untreated flares	Day 1 to Day 365
Time to initiation of first treatment for new or worsening disease activity	Day 1 to Day 365
Number of participants with Treatment Emergent Serious Adverse Events (TESAEs)	Day 1 to Day 2273
Number of participants with Treatment Emergent Adverse Events (TEAEs)	Day 1 to Day 2273
Annualized flare rate for treated flares	Day 1 to Day 365
GC use for the purpose of IgG4-RD disease control	Day 1 to Day 365

Trial Locations

Locations (7)

Viela Bio Investigative Site; 🇬🇧 Oxford, United Kingdom

Viela Bio Investigative Site 2; 🇪🇸 Barcelona, Spain

Viela Bio Investigative Site 1; 🇨🇳 Beijing, China

Viela Bio Investigative Site 3; 🇨🇳 Beijing, China

Viela Bio Investigative Site 4; 🇨🇳 Beijing, China

Viela Bio Investigative Site 5; 🇨🇳 Beijing, China

Viela Bio Investigative Siite; 🇲🇽 Tlalpan, Mexico